Research Projects
Pharmaceutical Companies
National Institutes of Health (NIH)
Other Projects
Pharmaceutical companies (US and international) contract with the Center for directed research studies as well as clinical trials for new drugs. The following companies (listed in alphabetical order) currently have or have had research contracts with the Center:
Pharmaceutical Companies
National Institutes of Health (NIH)
Other ProjectsPharmaceutical companies (US and international) contract with the Center for directed research studies as well as clinical trials for new drugs. The following companies (listed in alphabetical order) currently have or have had research contracts with the Center:
- AstraZeneca LLP
- Bristol-Meyers Pharmaceutical Group
- Danisco USA Inc.
- Forest Laboratories/Forest Research Institute
- GSK GlaxoSmithKline (and predecessors)
- Hoffman La Roche
- ICON
- MEDTAP/TAP
- Microbia
- Novartis Pharmaceuticals
- Otsuka
- Pain Therapeutics
- Pfizer Corp.
- Procter & Gamble Co.
- Presutti
- Prometheus Pharmaceuticals
- Regeneron Pharmaceuticals
- Salix Pharmaceuticals
- Sandoz Corporation
- Solvay Pharmaceuticals
- Sucampo Pharmaceuticals
- TAP Holdings
- Theravance
- Tioga
- Trine Pharmaceuticals
CHTF919A-US-32 (Drossman, PI) -- Novartis Pharmaceuticals
Clinical, Physiological and Psychological Differences Among Subgroups of IBS: A Comparison of IBS with Constipation/Mixed, IBS with Diarrhea/Mixed, and Alternators
Clinical, Physiological and Psychological Differences Among Subgroups of IBS: A Comparison of IBS with Constipation/Mixed, IBS with Diarrhea/Mixed, and Alternators
CHTF919EUS54 (Whitehead, PI) -- Novartis Pharmaceuticals
CONQUEST Study: Impact of chronic constipation
CONQUEST Study: Impact of chronic constipation
CHTF919-US-32 (Drossman, PI) - Novartis Pharmaceuticals
Proposal to Compare Rome II with Rome III Irritable Bowel Syndrome
Proposal to Compare Rome II with Rome III Irritable Bowel Syndrome
CHTF919D2302 (Ringel, PI) -- Novartis Pharmaceuticals
A 6-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess to Efficacy and Safety of Oral (Drug) and Placebo in Female Patients with Dyspepsia (extension is HTF919D2302E1)
A 6-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess to Efficacy and Safety of Oral (Drug) and Placebo in Female Patients with Dyspepsia (extension is HTF919D2302E1)
(Ringel, PI) -- GlaxoSmithKline/GSK
Genetic Surrogate Markers for Irritable Bowel Syndrome Susceptibility, Co-Morbidity and Disease Characterization
Genetic Surrogate Markers for Irritable Bowel Syndrome Susceptibility, Co-Morbidity and Disease Characterization
TRN-002-20 (Drossman and Dalton, Co-PI) -- Trine Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of (Drug) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of (Drug) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
05IBD05 (Drossman and Dalton, Co-PI) -- Prometheus Pharmaceuticals
Procurement of serum samples from irritable bowel syndrome (IBS) subjects for use in development of a diagnostic test for inflammatory bowel disease (IBD)
Procurement of serum samples from irritable bowel syndrome (IBS) subjects for use in development of a diagnostic test for inflammatory bowel disease (IBD)
SPI/0211SIB-0432 (Drossman and Dalton, Co-PI) -- Sucampo Pharmaceuticals
A 12-Week, Multicenter, Double-Blind, Randomized Efficacy and Safety Study of (Drug) in Subjects with Constipation-Predominant Irritable Bowel Syndrome (Phase III)
A 12-Week, Multicenter, Double-Blind, Randomized Efficacy and Safety Study of (Drug) in Subjects with Constipation-Predominant Irritable Bowel Syndrome (Phase III)
(Ringel, PI) -- Danisco USA Inc.
Clinical Efficacy of Probiotic Bacteria in Patients with IBS, Functional Diarrhea or Functional Bloating
Clinical Efficacy of Probiotic Bacteria in Patients with IBS, Functional Diarrhea or Functional Bloating
DEX-MD-20 (Drossman and Dalton, Co-PI) -- Forest Research Institute
A Phase II Study to Investigate the Safety and Efficacy of (Drug) for the Relief of Symptoms of Functional Dyspepsia
A Phase II Study to Investigate the Safety and Efficacy of (Drug) for the Relief of Symptoms of Functional Dyspepsia
ASMP2003 (Drossman and Dalton, Co-PI) -- Tioga
A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of (Drug) in Subjects with Irritable Bowel Syndrome
A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of (Drug) in Subjects with Irritable Bowel Syndrome
MCP 103-004 (Drossman and Dalton, Co-PI) -- Microbia
A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of (Drug) Administered for 14 Days at 100 ug, 300 ug, 1000 ug, or placebo to patients with chronic constipation
A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of (Drug) Administered for 14 Days at 100 ug, 300 ug, 1000 ug, or placebo to patients with chronic constipation
TD-5108 (Drossman and Dalton, Co-PI) -- Theravance
A Randomized, Placebo-Controlled, Double-Blind Study of (Drug) for the Treatment of Chronic Constipation
A Randomized, Placebo-Controlled, Double-Blind Study of (Drug) for the Treatment of Chronic Constipation
IRUSE SOM0313 (Shaheen, PI) -- AstraZeneca LLP
Chronic cough and reflux disease: a Randomized, double-blind, placebo-controlled trial
Chronic cough and reflux disease: a Randomized, double-blind, placebo-controlled trial
D9612L00084 (Shaheen, PI) -- AstraZeneca LLP
An investigation of the prevalence of clinically relevant esophageal mucosal pathology (EMP) in (drug) users
An investigation of the prevalence of clinically relevant esophageal mucosal pathology (EMP) in (drug) users
(Ringel, PI) -- Salix Pharmaceuticals
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 and 1100 mg) of Rifaximin administered BID for either two or four weeks in the treatment of patients with diarrhea-predominant Irritable Bowel Syndrome
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 and 1100 mg) of Rifaximin administered BID for either two or four weeks in the treatment of patients with diarrhea-predominant Irritable Bowel Syndrome